World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
48
Citations
9101
World Ranking
4428
National Ranking
52

Best Publications

  • Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.

    Hernando Knobel;Jordi Alonso;José L Casado;Julio Collazos

  • Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients.

    Unknown

  • Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain.

    J. Berenguer;P. Ryan;J. Rodríguez-Baño;I. Jarrín

  • Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.

    Esteban Martínez;Juan A. Arnaiz;Daniel Podzamczer;David Dalmau

  • Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study

    Luisa Sorlí;Sonia Luque;Santiago Grau;Núria Berenguer

  • Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

    Esteban Martinez;María Larrousse;Josep M Llibre;Felix Gutierrez

  • Osteopenia in HIV-infected patients: is it the disease or is it the treatment?

    Unknown

  • Eosinophil count and neutrophil-lymphocyte count ratio as prognostic markers in patients with bacteremia: a retrospective cohort study.

    Roser Terradas;Santiago Grau;Jordi Blanch;Marta Riu

  • A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

    Daniel Podzamczer;Elena Ferrer;Ezequiel Consiglio;José Maria Gatell

  • Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients.

    Rosario Palacios;Francisco Jiménez-Oñate;Manuela Aguilar;Maria José Galindo

  • Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

    José R Arribas;Pierre-Marie Girard;Roland Landman;Judit Pich

  • Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.

    Judit Villar-García;Juan J. Hernández;Robert Güerri-Fernández;Alicia González

  • HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: A population-based cohort study

    Robert Güerri-Fernandez;Peter Vestergaard;Cristina Carbonell;Hernando Knobel

  • Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.

    Jose R Arribas;Rafael Delgado;Alberto Arranz;Rosa Muñoz

  • Hypertension in HIV-Infected Patients: Prevalence and Related Factors

    Unknown

  • Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.

    Federico Pulido;Esteban Ribera;María Lagarde;Ignacio Pérez-Valero

  • Adherence and Effectiveness of Highly Active Antiretroviral Therapy

    Unknown

  • Subclinical Carotid Atherosclerosis in HIV-Infected Patients Role of Combination Antiretroviral Therapy

    Unknown

  • Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

    Chloe Orkin;Jean-Michel Molina;Eugenia Negredo;José R Arribas

  • Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

    Unknown

Frequent Co-Authors

Pere Domingo
Pere Domingo Autonomous University of Barcelona
Jose R. Arribas
Jose R. Arribas Hospital Universitario La Paz
Antonio Rivero
Antonio Rivero Instituto Maimónides de Investigación Biomédica de Córdoba
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
José M. Miró
José M. Miró University of Barcelona
Juan Berenguer
Juan Berenguer Hospital General Universitario Gregorio Marañón
Santiago Moreno
Santiago Moreno Hospital Universitario Ramón y Cajal
Federico Pulido
Federico Pulido Complutense University of Madrid
Daniel Podzamczer
Daniel Podzamczer Bellvitge University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Hernando Knobel